세계의 유전자 변형 치료 시장 규모는 2025년 148억 달러에서 2030년 말에는 321억 달러에 달할 것으로 예상되며, 2025년부터 2030년까지 16.8%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.
북미의 유전자 변형 치료 시장 규모는 2025년 73억 달러에서 2030년 말에는 164억 달러에 달할 것으로 예상되며, 2025년부터 2030년까지 17.7%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.
유럽의 유전자 변형 치료 시장 규모는 2025년 41억 달러에서 2030년 말까지 86억 달러에 달할 것으로 예상되며, 2025년부터 2030년까지 16.3%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.
세계의 유전자 변형 치료제(유전자 재조합치료) 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 기술 동향, 시장 규모 추이 및 예측, 각종 부문별/지역별 상세 분석, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 주요 요약
시장 전망
조사 범위
시장 요약
시장 역학과 성장요인
신기술
부문 분석
지역 분석
결론
제2장 시장 개요
개요
Porter의 Five Forces 분석
거시경제 요인 분석
미국 관세의 영향
지정학적 요인
제3장 유전자 변형 치료 : 기술과 응용
유전자 변형 치료
유전자 치료 기술
RNA 치료 기술
유전자 편집 기술
다양한 유형 유전자 편집 툴
유전자 편집 전달 방법법
유전자 변형 세포치료 기술
딜리버리 기술
임상 응용
제4장 시장 역학
시장 역학
시장 성장 촉진요인
희소 유전성 질환 유병률 증가
정밀의료에 대한 주목 증가
시장 성장 억제요인
유해사례 추적 및 장기 모니터링에 관한 규제 요건
유전자 편집 기술에 관한 윤리적 우려
유전자 변형 치료 고비용
시장 기회
유전자 변형 치료 응용 영역 확대
유전자 변형 세포치료 기성품
제5장 신기술과 파이프라인 분석
중요 포인트
신기술
CRISPR 생체내 전달
개량 Cas 바리안트
RNAi 전달 시스템 진보
RNA 편집
파이프라인 분석
RNA 치료
유전자 편집 치료
유전자 치료와 유전자 변형 세포치료
제6장 시장 세분화 분석
세분화 내역
시장 분석 : 플랫폼 기술별
중요 포인트
RNA 치료
유전자 변형 세포치료
유전자 치료
유전자 편집
시장 분석 : 용도별
중요 포인트
종양
희귀질환
심혈관질환
근골격계 질환
혈액 질환
기타
분석 지역
시장 분석 : 지역별
중요 포인트
북미
유럽
아시아태평양
기타 지역
제7장 경쟁 정보
중요 포인트
업계 구조
RNA 치료 시장 기업 점유율 분석
유전자 치료 시장 기업 점유율 분석
유전자 변형 세포치료 시장 기업 점유율 분석
전략 분석
제8장 유전자 변형 치료 시장 지속가능성 : ESG 관점
ESG : 서론
ESG 리스크 평가
결론
제9장 부록
조사 방법
출전
약어
기업 개요
ALNYLAM PHARMACEUTICALS INC.
AMGEN INC.
BIOGEN
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
FERRING
GENETIX BIOTHERAPEUTICS INC.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON
LILLY USA LLC.
NOVARTIS AG
NOVO NORDISK A/S
SANOFI
SAREPTA THERAPEUTICS INC.
VERTEX PHARMACEUTICALS INC.
신흥 스타트업 기업/시장 디스럽터
LSH
영문 목차
영문목차
The global market for genetic modification therapies is estimated to grow from $14.8 billion in 2025 to reach $32.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 16.8% from 2025 through 2030.
The North American market for genetic modification therapies is estimated to grow from $7.3 billion in 2025 to reach $16.4 billion by the end of 2030, at a CAGR of 17.7% from 2025 through 2030.
The European market for genetic modification therapies is estimated to grow from $4.1 billion in 2025 to reach $8.6 billion by the end of 2030, at a CAGR of 16.3% from 2025 through 2030.
Report Scope
The report provides an overview of genetic modification therapies clinical applications: gene therapies, genetically modified cell therapies, RNA therapies and gene editing market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. In this report, the market is segmented based on platform technology, application and region.
Based on platform technology, the market is segmented into gene editing, gene therapy, gene-modified cell therapy and RNA therapy platforms. The application segment covers oncology, rare diseases, cardiovascular diseases, musculoskeletal conditions, hematological disorders and other applications. The gene therapy segment is segmented based on the delivery systems into adeno-associated virus (AAV), herpes simplex virus (HSV)-1, lentivirus and others. The RNA therapy segment is segmented into antisense oligonucleotides, small interfering RNAs and others based on type.
The report also focuses on the regional segmentation of the market. The regions covered in this study include North America, Europe, Asia-Pacific, and the Rest of the World, with a focus on major countries in these regions.
The report also includes major driving trends and restraints that affect the market and vendor landscape. It analyzes environmental, social and corporate governance (ESG) developments, discussing pipeline activities and emerging technologies related to the market. The report concludes with an analysis of the competitive landscape and industry structure. It also has a dedicated section of company profiles that covers details of leading companies. The report does not include mRNA vaccines.
Report Includes
103 data tables and 63 additional tables
Overview and an analysis of the global market for clinical applications of genetic modification therapies
In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
Evaluation of the current market size and revenue growth prospects specific to the genetic modification therapies, accompanied by a market share analysis by platform technology, application and region
Analysis of current and future demand in the genetic modification therapies, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
Review of gene editing, gene therapy, CAR T-cell therapy, RNA therapy and lentiviral production, and discussion of how they are playing a key role in genetic modification therapies
Analysis of drivers, challenges and opportunities affecting market growth
Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
Market share analysis of the key market participants of the industry, along with their research priorities, product portfolios, global rankings and competitive landscape
Profiles of the leading companies, including Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Novartis AG, Bristol-Myers Squibb Co., and Sarepta Therapeutics Inc.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Overview
Porter's Five Forces Analysis
Threat of New Entrants (Low)
Bargaining Power of Suppliers (Moderate)
Bargaining Power of Buyers (Moderate)
Threat of Substitute (Low)
Industry Rivalry (High)
Macroeconomic Factors Analysis
Impact of the U.S. Tariffs
Geopolitical Factors
Chapter 3 Genetic Modification Therapies: Technology and Applications
Genetic Modification Therapies
Gene Therapy Technologies
RNA Therapy Technologies
Gene Editing Technologies
Different Types of Genome Editing Tools
Delivery Methods of Genome Editing
Gene-Modified Cell Therapy Technologies
Delivery Technologies
Clinical Applications
Chapter 4 Market Dynamics
Market Dynamics
Market Drivers
Increasing Prevalence of Rare Genetic Disorders
Growing Focus on Precision Medicine
Market Restraints
Regulatory Requirements on Adverse Event Tracking and Long-Term Monitoring
Ethical Concerns on Genome Editing Techniques
High Cost of Genetic Modification Therapies
Market Opportunities
Expanding Application Areas of Genetic Modification Therapies
Off-the-Shelf Products in Gene-Modified Cell Therapies
Chapter 5 Emerging Technologies and Pipeline Analysis
Key Takeaways
Emerging Technologies
In Vivo Delivery of CRISPR
Improved Cas Variants
Advances in RNAi Delivery Systems
RNA Editing
Pipeline Analysis
RNA Therapies
Gene Editing Therapies
Gene Therapies and Gene-Modified Cell Therapies
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis by Platform Technology
Key Takeaways
RNA Therapy
Gene-Modified Cell Therapy
Gene Therapy
Gene Editing
Market Analysis by Application
Key Takeaways
Oncology
Rare Diseases
Cardiovascular Diseases
Musculoskeletal Conditions
Hematological Disorders
Others
Geographic Breakdown
Market Analysis by Region
Key Takeaways
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Key Takeaways
Industry Structure
Company Share Analysis of the RNA Therapies Market
Company Share Analysis of the Gene Therapies Market
Company Share Analysis of the Gene-Modified Cell Therapies Market
Strategic Analysis
Chapter 8 Sustainability in the Genetic Modification Therapies Market: An ESG Perspective
